Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quinagolide for Preventing OHSS in Women Undergoing Controlled Ovarian Hyperstimulation
NCT00329693Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jun 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of quinagolide in ovarian hyperstimulation syndrome (OHSS) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Ovarian Hyperstimulation Syndrome. Started Jun 2006; status: completed.
02
Drugs
quinagolide
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT00329693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329693.